Pulmonary Disease Doctors in Saint Clair Shores, MI Accepting Medicare

5 Pulmonary Disease doctors found. Showing 1 - 5

Kimberley Demerle, M.D. Internal Medicine - Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 21000 E 12 Mile Rd Ste 112, Saint Clair Shores, MI 48081 Phone: 586-772-5550    Fax: 586-772-2470

Dr. Christopher W Hughes, M.D. Internal Medicine - Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 21000 E 12 Mile Rd Ste 112, Saint Clair Shores, MI 48081 Phone: 586-772-5550    Fax: 586-772-2470

Dr. William A Ventimiglia, M.D. Internal Medicine - Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 21000 E 12 Mile Rd Ste 112, Saint Clair Shores, MI 48081 Phone: 586-772-5550    Fax: 586-772-2470

Dr. Kevin J Grady, M.D. Internal Medicine - Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 25319 Little Mack Ave, Saint Clair Shores, MI 48081 Phone: 586-772-5550    Fax: 586-772-1706

Alfonso V O'neill, M.D. Internal Medicine - Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 25631 Little Mack Ave Ste 202, Saint Clair Shores, MI 48081 Phone: 586-588-9813    Fax: 586-588-9814

News Archive

Vaccine-related rubella virus causes harm in some patients with primary immunodeficiency disorders

Some patients with rare primary immunodeficiency disorders may be at risk for infection by rubella virus, and possibly serious skin inflammation, after receiving the rubella vaccine, usually administered as part of the measles-mumps-rubella (MMR) vaccine.

HIV vaccine candidate trialed in Sub-Saharan Africa falls short

An HIV vaccine candidate trialed in Sub-Saharan Africa offers no substantial protection against HIV infection among young women, the study organizers say.

GSK and Valeant receive FDA Complete Response letter for ezogabine

GlaxoSmithKline and Valeant Pharmaceuticals International, Inc. announced receipt of a Complete Response letter from the U.S. Food and Drug Administration (FDA) for the New Drug Application (NDA) for ezogabine, an investigational anti-epileptic drug being studied for the adjunctive treatment of adults with partial-onset seizures.

Bracelet warns of too much sun exposure

Scientists in Britain have come up with what appears a very sensible idea - a team at Strathclyde University in Scotland have developed an early warning sunburn indicator - it comes in the form of a thin strip which turns pink after too much exposure to ultra-violet light.

Read more Medical News

› Verified 3 days ago